Coagulopathy of COVID-19 and antiphospholipid antibodies.
作者信息
Connell Nathan T, Battinelli Elisabeth M, Connors Jean M
机构信息
Brigham and Women's Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
出版信息
J Thromb Haemost. 2020 Sep;18(9):E1-E2. doi: 10.1111/jth.14893. Epub 2020 May 28.
Abstract
摘要
相似文献
1
Coagulopathy of COVID-19 and antiphospholipid antibodies.
J Thromb Haemost. 2020 Sep;18(9):E1-E2. doi: 10.1111/jth.14893. Epub 2020 May 28.
2
Antigens and Antibodies of the Antiphospholipid Syndrome as New Allies in the Pathogenesis of COVID-19 Coagulopathy.
Int J Mol Sci. 2022 Apr 29;23(9):4946. doi: 10.3390/ijms23094946.
3
Antiphospholipid Antibodies in Critically Ill Patients With COVID-19.
Arthritis Rheumatol. 2020 Dec;72(12):1998-2004. doi: 10.1002/art.41425. Epub 2020 Oct 7.
4
Prevalence and clinical significance of antiphospholipid antibodies in patients with coronavirus disease 2019 admitted to intensive care units: a prospective observational study.
Rheumatol Int. 2021 Jul;41(7):1243-1252. doi: 10.1007/s00296-021-04875-7. Epub 2021 May 5.
5
Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome.
Lupus. 2022 Jul;31(8):974-984. doi: 10.1177/09612033221102073. Epub 2022 May 20.
6
Reality Check on Antiphospholipid Antibodies in COVID-19-Associated Coagulopathy.
Arthritis Rheumatol. 2021 Jan;73(1):173-174. doi: 10.1002/art.41472. Epub 2020 Dec 5.
7
Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients.
J Thromb Thrombolysis. 2020 Oct;50(3):580-586. doi: 10.1007/s11239-020-02182-9.
8
Could antiphospholipid antibodies contribute to coagulopathy in COVID-19?
J Am Acad Dermatol. 2020 Sep;83(3):e249. doi: 10.1016/j.jaad.2020.06.003. Epub 2020 Jun 4.
9
Antiphospholipid Antibodies and Infection: .
Front Immunol. 2021 Jun 16;12:687534. doi: 10.3389/fimmu.2021.687534. eCollection 2021.
10
Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19.
N Engl J Med. 2020 Apr 23;382(17):e38. doi: 10.1056/NEJMc2007575. Epub 2020 Apr 8.
引用本文的文献
1
Is lupus anticoagulant testing with dilute Russell's viper venom clotting times reliable in the presence of inflammation?
Res Pract Thromb Haemost. 2024 Jul 26;8(6):102536. doi: 10.1016/j.rpth.2024.102536. eCollection 2024 Aug.
2
Cognitive dysfunctions in the course of SARS‑CoV‑2 virus infection, including NeuroCOVID, frontal syndrome and cytokine storm (Review).
Biomed Rep. 2024 May 16;21(1):103. doi: 10.3892/br.2024.1791. eCollection 2024 Jul.
3
Emerging patterns of hypercoagulability associated with critical COVID-19: A review.
Trends Anaesth Crit Care. 2020 Oct;34:4-13. doi: 10.1016/j.tacc.2020.07.004. Epub 2020 Jul 9.
4
Lupus anticoagulants as a prospective independent predictor in COVID-19 patients.
Int J Lab Hematol. 2023 Apr;45(2):163-169. doi: 10.1111/ijlh.14003. Epub 2022 Dec 10.
5
Tissue factor in COVID-19-associated coagulopathy.
Thromb Res. 2022 Dec;220:35-47. doi: 10.1016/j.thromres.2022.09.025. Epub 2022 Oct 1.
6
Coagulation Disorders and Thrombosis in COVID-19 Patients and a Possible Mechanism Involving Endothelial Cells: A Review.
Aging Dis. 2022 Feb 1;13(1):144-156. doi: 10.14336/AD.2021.0704. eCollection 2022 Feb.
7
Ischemic Priapism in a 12 Year Old Patient Associated With Coronavirus Disease 2019 (COVID-19): A Case Report.
Urology. 2022 Jul;165:316-318. doi: 10.1016/j.urology.2022.01.022. Epub 2022 Jan 23.
8
Bilateral renal infarction with COVID-19 pneumonia: a case report.
Oxf Med Case Reports. 2021 Dec 28;2021(11-12):omab121. doi: 10.1093/omcr/omab121. eCollection 2021 Nov-Dec.
9
COVID-19 and immunothrombosis: Pathophysiology and therapeutic implications.
Crit Rev Oncol Hematol. 2021 Dec;168:103529. doi: 10.1016/j.critrevonc.2021.103529. Epub 2021 Nov 17.
10
Pathophysiology of Antiphospholipid Syndrome.
Thromb Haemost. 2022 Jul;122(7):1085-1095. doi: 10.1055/a-1701-2809. Epub 2021 Nov 18.
Zotero 插件